IRIS PubliCatt

Papa, Alfredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.778
NA - Nord America 3.716
AS - Asia 1.144
SA - Sud America 16
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
Totale 8.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.704
DE - Germania 1.446
SE - Svezia 710
CN - Cina 655
UA - Ucraina 388
IT - Italia 367
SG - Singapore 255
FR - Francia 216
IE - Irlanda 208
GB - Regno Unito 137
FI - Finlandia 101
IN - India 101
RU - Federazione Russa 94
TR - Turchia 50
BE - Belgio 31
IR - Iran 29
PL - Polonia 26
JP - Giappone 22
CA - Canada 9
CI - Costa d'Avorio 9
CZ - Repubblica Ceca 9
KR - Corea 9
CO - Colombia 8
EU - Europa 8
NL - Olanda 7
RO - Romania 7
BR - Brasile 5
HK - Hong Kong 5
HU - Ungheria 5
IL - Israele 5
EE - Estonia 4
GR - Grecia 4
BG - Bulgaria 3
BZ - Belize 3
CH - Svizzera 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
CL - Cile 2
PT - Portogallo 2
RS - Serbia 2
VN - Vietnam 2
AT - Austria 1
BD - Bangladesh 1
BH - Bahrain 1
DK - Danimarca 1
DZ - Algeria 1
ES - Italia 1
ID - Indonesia 1
IQ - Iraq 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
NG - Nigeria 1
PH - Filippine 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
VE - Venezuela 1
Totale 8.680
Salva come PNG Salva come JPEG
Città #
Chandler 921
Ashburn 287
Jacksonville 254
Dublin 206
San Mateo 191
Hangzhou 171
Singapore 161
New York 145
Ann Arbor 127
Nanjing 114
Dearborn 111
Wilmington 108
Boston 95
Nürnberg 92
Milan 84
Cattolica 82
Princeton 72
Moscow 67
Munich 59
Marseille 54
Los Angeles 50
Beijing 48
Izmir 48
Redwood City 48
Nanchang 46
Bremen 45
Lawrence 42
Houston 41
Redmond 41
Woodbridge 37
Boardman 36
Rome 31
Brussels 29
Fairfield 28
Seattle 27
Norwalk 26
Kunming 25
Helsinki 24
Kraków 24
Hebei 23
Augusta 22
Changsha 22
Shenyang 22
Trieste 22
Andover 20
Lancaster 20
Mountain View 20
Pune 19
Jiaxing 18
Kish 17
Detroit 16
Leawood 16
Shanghai 16
Chicago 15
Tianjin 13
University Park 13
Washington 13
Fremont 12
Hefei 10
Abidjan 9
Jinan 9
Lanzhou 9
Seoul 9
Zhengzhou 9
Bogotá 8
Costa Mesa 8
Guangzhou 8
Ardabil 7
Edinburgh 7
San Francisco 7
San Jose 7
Phoenix 6
San Diego 6
Simi Valley 6
Tokyo 6
London 5
Brno 4
Budapest 4
Cambridge 4
Frankfurt am Main 4
Hong Kong 4
Indiana 4
Lappeenranta 4
Tallinn 4
Tappahannock 4
Tel Aviv 4
Toronto 4
Amsterdam 3
Atlanta 3
Auburn Hills 3
Baotou 3
Belize City 3
Berlin 3
Cagliari 3
Changchun 3
Chelsea 3
Clearwater 3
Hounslow 3
Las Vegas 3
Lecco 3
Totale 4.655
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 315
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. 200
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 151
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 150
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 141
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 140
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 133
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 133
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 132
Early atherosclerosis in patients with inflammatory bowel disease. 131
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 131
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 130
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 128
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 127
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 120
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 118
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 118
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 117
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 117
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 114
Assessment of neurological manifestations in hospitalized patients with COVID-19 114
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 111
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 110
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 104
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 101
Use of infliximab in particular clinical settings: management based on current evidence. 95
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 95
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 95
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 91
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 91
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 90
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 89
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 88
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 87
-Extraintestinal manifestations in inflammatory Bowel disease. 86
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 85
A novel pathogenic role for microvasculature in inflammatory bowel disease. 84
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 83
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 82
Effect of moderate and heavy alcohol consumption on intestinal transit time 82
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 82
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 81
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 77
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 75
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 74
Differentiation affects the release of exosomes from colon cancer cells and their ability to modulate the behavior of recipient cells 73
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 73
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 72
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 69
Mucosal healing in ulcerative colitis: surveillance or colectomy? 68
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 67
Biological therapies for inflammatory bowel disease: research drives clinics. 66
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 65
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 65
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 63
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 63
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 63
A) Review article: inherited thrombophilia in inflammatory bowel disease. 61
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 61
Development and validation of predictive assessment of complicated diverticulitis score 61
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 61
Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. 59
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 59
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 58
Can we predict the efficacy of anti-TNF-α agents? 57
Hot topics in surgical management of acute diverticulitiss 57
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 53
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 53
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 52
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 52
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 52
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 51
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease 50
New therapeutic approach in inflammatory bowel disease. 50
The dica endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists: An international study 50
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 50
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 49
Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. 48
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 48
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 48
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 48
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 47
Biological therapies for inflammatory bowel disease: controversies and future options 46
Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations 46
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 46
The economic burden of diverticular disease 44
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. 44
Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa 43
Onset of severe perianal disease in Crohn's disease under treatment with infliximab: successful treatment with adalimumab and setons drainage. 43
Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). 43
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 43
A) CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. 42
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 42
Intestinal Microbiome Modulation During Coronavirus Disease 2019: Another Chance to Manage the Disease? 41
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease 40
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 40
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 40
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 39
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 38
Intima-media thickness in inflammatory bowel disease patients: a still open question. 36
Totale 7.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020790 0 0 77 37 80 124 96 44 75 36 139 82
2020/2021772 25 82 17 85 112 23 93 24 96 20 176 19
2021/20221.060 63 78 21 111 47 21 12 214 38 68 168 219
2022/20232.307 299 297 157 418 135 301 88 188 263 45 74 42
2023/20241.223 57 319 50 69 41 174 68 43 45 77 135 145
2024/2025201 60 88 53 0 0 0 0 0 0 0 0 0
Totale 8.824